drugset
drugset / Trial / NCT05080959

A Phase 2, Randomized, Double-Blind, Dose Escalation Study in Postoperative Pain Open Inguinal Herniorrhaphy

NCT05080959 ↗

Phase 2 Completed 105 enrolled Cali Pharmaceuticals LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a Phase 2b, randomized, double blind, placebo and active controlled study with an Ascending Dose Stage and an optional Dose Expansion Stage in subjects undergoing open inguinal herniorrhaphy with mesh.

Timeline

Start
2021-07-28
Primary completion
2021-12-31
Completion
2022-06-10

Drugs

EvaluationDrugModalityDoseRoute
Subject CPL-01 Unknown 200 mg Other
Subject CPL-01 Unknown 400 mg Other
Subject CPL-01 Unknown 600 mg Other
Subject Ropivacaine Other / unclassified 150 mg Other

Indications

hernia, double inguinal